This mAb specifically precipitates heterogeneous material of high MW, identified as perlecan, a major heparan-sulfate proteoglycan (HSPG) within all basement membranes and cell surfaces. It does not cross-react with laminin, fibronectin, or dermatran sulfate proteoglycan. Because of perlecan s strategic location and ability to store and protect growth factors, it has been strongly implicated in the control of tumor cell growth and metastatic behavior. Perlecan possesses angiogenic and growth-promoting attributes primarily by acting as a co-receptor for basic fibroblast growth factor (FGF-2). Suppression of perlecan causes substantial inhibition of neoplastic growth and neovascularization. Thus, perlecan is a potent inducer of neoplasm growth and angiogenesis in vivo and therapeutic interventions targeting this key modulator of tumor progression may improve neoplastic treatment.

Flow Cytometry: 0,5-1 µg/million cells in 0,1 ml Immunofluorescence: 0,5 - 1 µg/ml Immunohistochemistry (FFPE): 1 - 2 µg/ml for 30 min at RT (1) Prediluted format: incubate for 30 min at RT (2) Optimal dilution of the Perlecan antibody should be determined by the researcher.

1. Staining of formalin-fixed tissues requires boiling tissue sections in 10 mM Citrate buffer, pH 6,0, for 10 - 20 min followed by cooling at RT for 20 min
2. The prediluted format is supplied in a dropper bottle and is optimised for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.

Type: Primary
Antigen: HSPG2
Clonality: Monoclonal
Clone: A7L6
Conjugation: Unconjugated
Epitope:
Host: Rat
Isotype: IgG2a, kappa
Reactivity: Human, Monkey, Bovine, Pig, Mouse, Fish